In April, the listed company's repurchase enthusiasm was high, and this pharmaceutical company plans to repurchase more than 1.1 billion yuan

On April 11, the China Securities Regulatory Commission, the State-owned Assets Supervision and Administration Commission, and the All-China Federation of Industry and Commerce jointly issued the "Notice on Further Supporting the Healthy Development of Listed Companies", which put forward 12 requirements, among which listed companies are encouraged to repurchase shares for equity incentives and employee stock ownership plans
.
Support eligible listed companies to repurchase to stabilize stock prices
.
Listed companies shall be supported in accordance with the law to raise funds through various channels such as issuance of preferred shares and bonds to implement share repurchase
.
With the release of this favorable policy, the enthusiasm of listed companies for repurchase is high
.
According to industry statistics, as of April 19, 33 Shenzhen-listed companies have disclosed repurchase plans in April, and many of them plan to repurchase funds exceeding 1 billion yuan, such as Vanke A, Yunnan Baiyao, and SF Holding
.
Yunnan Baiyao announced at noon on April 8 that the company plans to use no more than 1.
11942 billion yuan of its own funds to repurchase the company's shares for the implementation of employee stock ownership plans or equity incentive plans
.
According to the announcement, the upper limit of the repurchase shares is 9 million shares, accounting for 0.
7016% of the company's current total share capital, and the lower limit of the repurchase shares is 4.
5 million shares, accounting for 0.
3508% of the company's current total share capital, and the repurchase price does not exceed 124.
38 yuan / share
.
Based on the upper limit of the number of repurchases of 9 million shares and the upper limit of the repurchase price of 124.
38 yuan per share, it is estimated that the repurchase amount will not exceed 1,119.
42 million yuan
.
The period for the repurchase of shares shall not exceed 12 months from the date when this repurchase plan is considered and approved at the general meeting of shareholders that considers the repurchase matter
.
The announcement shows that with the development and integration of cutting-edge technologies such as global biotechnology, artificial intelligence and big data, and the continuous deepening of the domestic "three medical" linkage reforms, to achieve sustainable survival and development in the future, the company needs to expand in a wider range and at a higher level.
The integration of market and product resources on a level, technological innovation and organizational change have become the key driving forces for the company's future strategic development
.
Facing the drastic changes in the external objective environment, with the concerted efforts and unremitting efforts of all employees, the company's main business has achieved stable and healthy development
.
In order to further promote the innovation, transformation and development of the enterprise, the company plans to implement share repurchase for the implementation of employee stock ownership plan or equity incentive plan, and continue to improve the long-term incentive and restraint mechanism for mutual benefit and win-win, so as to effectively combine the interests of shareholders, the company and the The interests of the core team are combined to enhance the overall value of the company
.
After the company's announcement on the repurchase of shares, it closed at 78.
11 yuan per share in mid-February 2021, which has dropped by nearly 51% from the historical high of 158.
28 yuan per share in mid-February 2021
.
It is worth mentioning that not long ago, Yunnan Baiyao announced that the purchase of major assets for the subscription of 666 million A-shares non-publicly issued by Shanghai Pharmaceuticals in 2021 has been completed, with a subscription capital of 10.
91 billion yuan
.
After the subscription was completed, Yunnan Baiyao held 18.
01% of Shanghai Pharmaceuticals shares, becoming the second largest shareholder of Shanghai Pharmaceuticals
.
The 2021 annual report shows that Yunnan Baiyao achieved a net profit of 2.
804 billion yuan attributable to its parent, a year-on-year decrease of 49.
17%.
This is the first time the company has experienced a decline in net profit attributable to its parent in the past 20 years
.
At the same time, the company announced that it will distribute cash dividends of RMB 16.
00 (tax included) and 4 bonus shares (tax included) for every 10 shares to all shareholders based on the total share capital on the date of equity registration when the distribution plan is implemented in the future.
share capital
.
In the annual report, the company attributed the decline in net profit attributable to the parent company to the impact of changes in the net value of securities and fund units held, which accounted for -55.
41% of total profits
.
However, the company is also optimizing investment.
The overall investment amount (including equity investment, non-equity investment and financial asset investment) has been reduced from 28.
133 billion yuan at the end of 2020 to 6.
896 billion yuan at the end of 2021, a year-on-year decrease of 75.
49%
.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyone
.